How safe is stem cell therapy for macular degeneration?
The safety of stem cell therapy for macular degeneration depends above all on how and where the cells are delivered.

When mesenchymal stromal cells (MSCs) are given by intravenous (IV) infusion, large safety analyses across many conditions show a favorable profile, with temporary fever as the most consistent side effect and no increased rates of infection, blood clots, cancer or death in controlled trials. In contrast, injecting cells directly into the eye outside of carefully designed clinical trials has caused severe and permanent vision loss in published cases. For this reason, any regenerative approach for age-related macular degeneration (AMD) should avoid unregulated eye injections and should never replace proven treatments such as anti-VEGF injections for wet AMD. At Stem Cell Mexico, AMD protocols are defined after a medical evaluation and an ophthalmology record review, and the route and its risks are explained before any decision.
This guide explains what is known about safety, which approaches carry the most risk and how to protect your vision while exploring options.
How AMD affects vision, and why caution matters
The macula is a small area at the center of the retina, only a few millimeters wide, responsible for the sharp central vision used to read, drive and recognize faces. In AMD, the support layer beneath the retina (the retinal pigment epithelium) and the light-sensing cells above it gradually deteriorate. In wet AMD, fragile abnormal blood vessels can leak and bleed. Because central vision depends on such a small and delicate structure, even minor complications such as inflammation, bleeding or traction on the retina can cause lasting damage. Side vision is usually preserved in AMD, which allows many people to remain independent; procedures that risk the whole eye, including peripheral vision, are therefore especially concerning. This is the main reason ophthalmologists insist on rigorous protocols for any intervention involving the eye.
Why route is the key safety question in AMD
Intravenous infusion
Cells circulate through the body and act through anti-inflammatory and immune-modulating signals. This route does not involve the eye directly. Its safety is supported by large analyses:
- A systematic review in EClinicalMedicine (Thompson and colleagues, 2020) of 55 randomized trials with 2,696 patients found that IV MSCs increased the risk of temporary fever but not of infusion toxicity, infection, thrombosis, malignancy or death.
- A 2026 analysis in Stem Cells Translational Medicine (Hum and colleagues) of 42 randomized trials with 2,280 patients receiving umbilical cord MSCs found the same pattern, with continued long-term monitoring recommended.
These studies were not in AMD specifically, but they describe the safety of the cell type and route.
Injections into the eye
Intravitreal (into the gel of the eye), subretinal (under the retina) and retrobulbar (behind the eye) injections are very different procedures. In regulated clinical trials, such as those testing retinal cells grown from pluripotent stem cells, they are performed by retina specialists under strict protocols. Outside such settings, serious harm has occurred.
The warning cases: what happened and why it matters
In 2017, The New England Journal of Medicine published a report (Kuriyan and colleagues) of three women with AMD who received intravitreal injections of cells derived from their own fat at a U.S. clinic, in both eyes on the same day, outside a regulated trial. Within days, they developed complications including retinal detachment, bleeding inside the eye and severe inflammation, and they suffered profound, permanent vision loss. The U.S. National Eye Institute (NEI) has highlighted these cases and others, including a patient who developed growths after cell injections behind the eyes, to explain that injected cells can behave unpredictably inside the eye.
The lessons are clear:
- The eye is extremely sensitive; complications can be irreversible.
- Both eyes should never be treated simultaneously with an experimental injection.
- Eye procedures should only be done by retina specialists within properly designed and supervised protocols.
- Being registered on a public trials website does not by itself mean a study is regulated or safe.
Standard AMD care must continue
According to the NEI, AMD management depends on the form and stage of disease:
- Wet AMD: anti-VEGF injections into the eye have strong evidence for preserving vision. Interrupting them can lead to rapid vision loss.
- Dry AMD: AREDS2 nutritional supplements are recommended for certain patients with intermediate or advanced disease, and newer treatments may slow geographic atrophy in selected cases.
- All patients: regular monitoring, home checks with an Amsler grid, not smoking, and managing blood pressure and cholesterol.
Any regenerative therapy must be considered in addition to, not instead of, this care.
AMD-specific safety considerations
- Active wet AMD: must be under treatment and monitored by a retina specialist. A regenerative procedure should be scheduled so it does not delay anti-VEGF injections.
- Recent eye surgery or injections: timing is coordinated with the ophthalmologist.
- Blood thinners: relevant for any injection and reviewed in advance.
- Cardiovascular health: many AMD patients are older and have heart disease or high blood pressure, which affect infusion planning and monitoring.
- Cancer history: we require at least five years of documented remission.
- Fall risk and low vision: travel and the clinic environment are planned to reduce the risk of falls.
How we reduce risk
- Review of ophthalmology records: visual acuity, OCT scans, fundus imaging, AMD type and current treatment.
- Choosing the least invasive appropriate route and explaining its specific risks before any decision.
- No interruption of proven treatment, with coordination with your eye doctor.
- Pre-treatment testing: complete blood count, metabolic panel, urinalysis and tumor markers.
- Quality-controlled cells: donor screening, infectious disease testing, and laboratory quality testing before release.
- Monitoring and observation after the procedure.
- Objective follow-up: comparing eye exams before and after treatment.
Planning your visit with low vision
People with AMD often have difficulty reading forms, recognizing faces or navigating unfamiliar places. Bring a companion if possible, ask for documents in large print or have them read aloud, and bring your glasses and magnifiers. Let the team know about your vision needs in advance so that transportation, signage and room arrangements can be adapted. Good lighting and an uncluttered room help reduce the risk of falls during your stay, especially after sedation or an infusion, when you may feel tired.
Safety and benefit are different questions
A treatment can be safe without improving vision. Research on cell replacement for AMD, such as transplanting retinal pigment epithelium grown from stem cells, is advancing in clinical trials, but it uses different cells, routes and surgical techniques than systemic MSC therapy. We do not promise vision restoration, and patients should be cautious with any claim that cell therapy offers "the same or better results" than proven treatments.
Regulatory context
The FDA has not approved stem cell products for AMD and has warned about unapproved eye treatments. In Mexico, establishments that handle stem cells operate under sanitary licenses from COFEPRIS. Ask exactly where and how the cells will be administered.
What our patients usually receive
Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:
- Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on the condition, body weight and medical review.
- One night at our facilities, sometimes two, with nursing and medical monitoring.
- Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
- Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.
Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.
Questions to ask any provider offering eye-related cell treatments
Before agreeing to any cell treatment for AMD, at any clinic, ask whether a retina specialist is involved, whether the study or protocol has ethics committee approval and regulatory oversight, whether both eyes would be treated at once (they should not be with experimental injections), what monitoring is planned in the days and weeks after the procedure, and who will manage complications. If the answers are vague, or if the provider discourages you from continuing treatment with your own eye doctor, consider that a warning sign.
Who may be a safe candidate
- Confirmed AMD with current ophthalmology records.
- Wet AMD, if present, actively treated and stable.
- Stable general and cardiovascular health.
- No active infection and no cancer within the past five years.
- Realistic goals focused on support and stability, with objective follow-up.
Signs to report after any treatment
Contact your eye doctor urgently for sudden vision loss, new distortion, a curtain or shadow in your vision, flashes or many new floaters, eye pain or redness. For systemic effects, report high or persistent fever, shortness of breath or chest pain.
Questions to ask during your evaluation
- Exactly where and how will the cells be administered?
- Will anything be injected into or around my eyes?
- How will my current AMD treatment continue?
- What evidence supports this approach for my form of AMD?
- How will we measure my vision before and after?
Bottom line
For macular degeneration, safety depends on the route: systemic MSC infusions have a reassuring general safety record, while unregulated injections into the eye have caused permanent vision loss. Regenerative therapy for AMD is a supportive approach and must never replace proven eye care. A medical evaluation can help determine whether this type of regenerative treatment is appropriate and safe for your eyes, goals and medical history.
References
- Kuriyan AE et al. Vision loss after intravitreal injection of autologous stem cells for AMD. The New England Journal of Medicine, 2017 (opens in a new tab)
- National Eye Institute (NEI, NIH): Putting stem cell-based therapies in context (opens in a new tab)
- National Eye Institute (NEI, NIH): Age-related macular degeneration (opens in a new tab)
- Thompson M et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine, 2020 (opens in a new tab)
- Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
